Insilico Medicine and CMS deepen CNS collaborationInsilico Medicine has signed an “AI-empowered” drug discovery collaboration with China Medical System Holdings (CMS). Insilico will combine its artificial intelligence (AI) platform and drug discovery capabilities with CMS's R&D expertise. “We are focused on rapidly delivering a once-weekly oral IL-23 therapy that combines best-in-class convenience with efficacy competitive with other emerging oral IL-23 therapies.” Insilico and Bora Pharmaceuticals sign $2.5bn AI drug discovery dealInsilico also unveiled a multi-target strategic alliance with Bora Pharmaceuticals, aimed at fusing Insilico's Pharma.AI discovery engine with Bora's manufacturing, quality and commercial infrastructure. Earlier this month, Insilico Medicine signed a discovery collaboration with Takeda worth up to $600 million in biobucks.